Does Rallies show Form 4 insider transactions for KLRA?

Yes. Rallies tracks KLRA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is KLRA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KLRA. It does not provide personalized investment advice.

KLRA (Kailera Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Kailera Therapeutics, Inc. Common Stock (KLRA) is a publicly traded the market company. As of May 21, 2026, KLRA trades at $20.10 with a market cap of $2.53B and a P/E ratio of 0.00. KLRA moved +2.34% today. Year to date, KLRA is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $19.01 to $28.23. Analyst consensus is strong buy with an average price target of $45.00. Rallies surfaces KLRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading KLRA stock inside the company?

Recent KLRA insider activity includes RTW INVESTMENTS, LP bought 500.00K, BAIN CAPITAL INVESTORS LLC bought 8.40M, Koppel Adam bought 1.56M, Bain Capital Life Sciences Investors, LLC bought 1.56M, and Kaplan Andrew T. bought 8.40M. Rallies tracks insider transaction dates, shares, prices, and estimated values.

KLRA Key Metrics

Key financial metrics for KLRA
Metric	Value
Price	$20.10
Market Cap	$2.53B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$28.23
52-Week Low	$19.01
Volume	1
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Recent KLRA Insider Trades

RTW INVESTMENTS, LP bought 500.00K (~$8.00M) on Apr 20, 2026.
BAIN CAPITAL INVESTORS LLC bought 8.40M (~$134.38M) on Apr 20, 2026.
Koppel Adam bought 1.56M (~$25.00M) on Apr 20, 2026.
Bain Capital Life Sciences Investors, LLC bought 1.56M (~$25.00M) on Apr 20, 2026.
Kaplan Andrew T. bought 8.40M (~$134.38M) on Apr 20, 2026.

Latest KLRA News

Kailera to Present Phase 1 Injection and Phase 2 Oral Ribupatide Data June 7-8 — May 13, 2026

KLRA Analyst Consensus

5 analysts cover KLRA: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.00.

Common questions about KLRA

Who is trading KLRA stock inside the company?: Recent KLRA insider activity includes RTW INVESTMENTS, LP bought 500.00K, BAIN CAPITAL INVESTORS LLC bought 8.40M, Koppel Adam bought 1.56M, Bain Capital Life Sciences Investors, LLC bought 1.56M, and Kaplan Andrew T. bought 8.40M. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for KLRA?: Yes. Rallies tracks KLRA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is KLRA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KLRA. It does not provide personalized investment advice.